通讯作者: 白晓红, lunwen200901@163.com

DOI：10.12201/bmr.202608.00022

Progress in the study of combining Chinese and Western medicine to regulate immune imbalance affecting paediatric drug-resistant mycoplasma pneumonia

• 摘要：肺炎支原体肺炎（mycoplasma pneumoniae pneumonia，MPP）是由感染肺炎支原体引起的肺部炎症，临床以发热、咳嗽为主要症状，较重者可出现持续高热、气促、发绀、喘息等。近年来，MPP在世界各地出现阶段性范围性爆发趋势，有关大环内酯类耐药的报道增多，众学者进行了调节免疫失衡治疗MPP的研究。中医通过清热化痰、益气养阴等治法可调节免疫失衡，降低炎症因子水平，西医联合小剂量糖皮质激素或丙种球蛋白抑制过度炎症反应。二者协同干预可更精准调控，改善免疫紊乱状态，从而缩短病程、减少重症转化风险。本文从发病机制、临床应用等角度，综述中西医疗法如何调节免疫失衡，为MPP治疗提供新的研究方向。

  关键词： 中医儿科；中西医结合；肺炎支原体；肺炎; ; ; 

   

  Abstract: s? Mycoplasma pneumoniae is a kind of lung inflammation caused by infection with Mycoplasma pneumoniae, which can involve bronchi, fine bronchioles, alveoli and interstitium of the lungs, and the clinical manifestations mainly include fever and cough. In more severe cases, persistent high fever, shortness of breath, cyanosis and wheezing may occur. In recent years, Mycoplasma pneumonia has shown a tendency to stage-wide outbreaks around the world, and reports about macrolide resistance have increased, and many scholars have conducted a series of studies on the regulation of immune imbalance by Chinese and Western medicine for the treatment of paediatric drug-resistant Mycoplasma pneumonia. In this paper, we review how Chinese and Western medical therapies regulate the immune imbalance from three perspectives: the pathogenesis of Mycoplasma pneumoniae, the mechanism of drug resistance, and the regulation of immune imbalance, so as to provide a new research direction for the treatment of paediatric drug-resistant Mycoplasma pneumonia.

  Key words: Chinese paediatrics; Mycoplasma pneumoniae pneumonia; macrolide resistance; immune imbalance

  提交时间：2026-08-09

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 王美林, 杨鹏丽, 庞高峰, 郭峥. 基于Citespace的中医药治疗肺炎支原体肺炎可视化分析. 2026. doi: 10.12201/bmr.202604.00142

  施明杰, 叶洪舟, 袁琛. 大环内酯类耐药肺炎支原体肺炎患儿发展为重症肺炎的危险因素分析及预测模型构建. 2024. doi: 10.12201/bmr.202409.00021

  p>何海玲, 陆建良, 冯媛, 卢艳玲. 儿童重症肺炎支原体肺炎的临床特点分析. 2025. doi: 10.12201/bmr.202505.00038

  时小淋, 汤冬静, 吴美慧. 儿童肺炎支原体支气管肺炎和大叶性肺炎的相关危险因素分析. 2025. doi: 10.12201/bmr.202507.00035

  张雪, 李菲凡, 张水堂. 混合感染及耐药基因对肺炎支原体肺炎患儿临床特征的影响差异. 2024. doi: 10.12201/bmr.202412.00025

  吕海涛, 沈腾腾, 许会卿, 徐月波, 郑吉善. 多西环素治疗8岁以下儿童肺炎支原体肺炎的疗效分析. 2025. doi: 10.12201/bmr.202509.00001

  王媛媛, 常艳美, 于丽娟, 孟淑萍. 肺炎支原体RNA检测在儿童肺炎支原体肺炎诊断和治疗中的价值研究. 2025. doi: 10.12201/bmr.202506.00025

  李会君, 霍洁, 杭菲菲, 徐静, 管峥. 血清IgE、LDH及IL-18对儿童难治性肺炎支原体肺炎的早期识别价值. 2026. doi: 10.12201/bmr.202606.00009

  刘嘉欣, 张小华, 杨逸彤. CARDS TX在儿童肺炎支原体感染中的研究进展. 2025. doi: 10.12201/bmr.202506.00057

  马亚鑫, 朱晓伟, 李淑琼, 李云翔, 孙永红. 儿童重症肺炎支原体肺炎早期预测的研究进展. 2025. doi: 10.12201/bmr.202504.00073

• 序号	提交日期	编号	操作
  1	2026-03-26	10.12201/bmr.202608.00022V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论